● Recruiting

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Condition: Metastatic Castration-resistant Prostate Cancer · Sponsor: Sun Yat-sen University

PhaseN/A

Planned participants30

Who can joinMale, 18 Years to 75 Years

Healthy volunteersNo

About this study

To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment

This description comes directly from the study's public registry record.

Talk to the study team

Yonghong Li, M.D. · +020-87343656 · liyongh@sysucc.org.cn

Jun Wang, M.D. · +020-87343656 · wangjun2@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05116579